An interventional study of Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical. and Arterial blood gas (ABG) and serum bicarbonate level in COPD, sponsored by Beth Israel Deaconess Medical Center. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-04.
Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment
Despite growing evidence showing benefit (in both clinical and cost standpoints), only a small percentage of COPD patients with chronic hypercapnic respiratory failure are managed with nocturnal ventilatory support. There is uncertainty of the value of aggressive nocturnal ventilation, especially polysomnographic estimation of therapy and home transcutaneous CO2 tracking.
The driving goal behind this project is to develop and implement a streamlined and comprehensive program for nocturnal ventilator management of patients with advanced, hypercapnic COPD.
The purpose of this protocol is to perform a prospective, randomized, comparative effectiveness clinical trial to evaluate the role of non-invasive nocturnal ventilation in addition to usual care, compared to usual care alone in the management of adult COPD patients with chronic hypercapnic respiratory failure. The study will focus on the primary end-points of time to hospital re-admission for acute exacerbation of COPD and/or an episode of acute on chronic hypercapnic respiratory failure, in addition to other clinically relevant outcomes including patient health-related quality of life, sleep quality indices, and gas exchange parameters. Approximately 300 BIDMC adult patients will be recruited and each patient monitored over a period of 12 months.
186 studies on the registry are indexed under Hypercapnia; 34 are open to participants now.
Browse Hypercapnia studies →Beth Israel Deaconess Medical Center is the lead sponsor of 560 studies on the registry; 80 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 61 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male or female aged ≥ 18 years with advanced hypercapnic COPD
Women and minorities will be recruited in numbers reflecting representation in the Boston Metropolitan community which is approximately 84% Caucasian, 9% African American, 5% Hispanic American, and 2% Asian American, as the knowledge gained can apply to individuals of all ethnic background and gender.
We do not wish to limit our sample to a highly selected group of patients, to allow for more generalizable results.
Exclusion Criteria:
Subjects will be excluded from participation in the study for a history of:
Usual care follows the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.
Diagnostic Test: Arterial blood gas (ABG) and serum bicarbonate level · Diagnostic Test: Overnight home oximetry and transcutaneous CO2 monitoring
Usual care for COPD based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines plus use of nocturnal ventilator device using the Breas VIVO 50 home ventilator, Breas Medical (or any newer models as available).
Device: Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical. · Diagnostic Test: Arterial blood gas (ABG) and serum bicarbonate level · Diagnostic Test: Overnight home oximetry and transcutaneous CO2 monitoring
In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time. For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring.
Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
Time to readmission or death
time to re-admission for acute exacerbation of COPD and/or acute on chronic hypercapnic respiratory failure or death
Time frame: within 12 months
Patient health related quality of life (HRQOL)
The RAND SF-36, a 36-question multiple choice QOL form will be used to assess general health perception. The questions target eight health domains or scales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal/emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and one's perceived change in health. There is a 2-step process used in scoring, such that the score for each of the scales represent the average for all item in the scale that were answered. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Next, items in the same scale are averaged together to create 8 scale scores. The lower the score the more disability and the higher the score the less disability. Scores will be assessed at baseline, 3 and 12 months for usual care and usual care plus ventilation support for all subjects.
Time frame: 12 months
Dyspnea scale
change in results of the Medical Research Council dyspnea scale, a categorical scale from 1-5, higher score =more limitation on daily activity due to breathlessness. Scores will be assessed at baseline, 3 and 12 months for usual care and usual care plus ventilation subjects.
Time frame: 12 months
Gas exchange
Change in CO2 from ABG and serum bicarbonate
Time frame: 12 months
General health status
St. George's Respiratory questionnaire, a 50 item questionnaire that measures health status in patients with COPD will be completed at baseline, and after 3 and 12 months in all subjects. For this questionnaire, a score of 0 = best QOL, and a score of 100 = worst QOL. The questions focus on three areas - symptoms, activity, and impact (psycho-social).
Time frame: 12 months
Ambulatory BP profiles
In a subset of subjects (from usual care and usual care plus ventilation groups), 24-hour ambulatory BP monitoring will be conducted (at baseline and after 3 months) to assess for change in 24-hour and nocturnal systolic, diastolic and mean BPs.
Time frame: 3 months compared to baseline
Inflammatory biomarkers
High sensitivity C-reactive protein \[hs-CRP\], units mg/ml, can be measured from peripheral blood. Elevated levels reflect increased systemic inflammation. Studies have shown that individuals with elevated levels (above 2 mg/ml) are at increased risk of cardiovascular disease. During this trial, HR-CRP will be obtained at baseline and after 3 and 12 months in subjects to assess whether there is a favorable change in subjects treated with nocturnal ventilation + usual care, as compared to usual care.
Time frame: 3 and 12 months compared to baseline
Plan to share: Undecided — Subject information and biological samples will be used and shared with the researchers involved in this study to conduct the research.
No publications or documents are linked to this record.
This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beth Israel Deaconess Medical Center